To overcome this potential mechanism of resistance, dual TORC1/TORC2 inhibitors26, 27 were evaluated and found to be more cytotoxic than rapamycin in primary samples of a variety of lymphoid neoplasms exposed ex vivo.28, 29. The gene discussed is CRTC1; the disease is lymphoid neoplasm.